BiomX (NYSEMKT:PHGE) Stock Price Down 14.9% – Time to Sell?

BiomX Inc. (NYSEMKT:PHGE) shares dropped 14.9% during trading on Thursday . The company traded as low as $0.72 and last traded at $0.63. Approximately 53,300 shares traded hands during trading, a decline of 14% from the average daily volume of 61,836 shares. The stock had previously closed at $0.74.

BiomX Stock Performance

The stock has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $0.79. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The stock has a market capitalization of $11.43 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.

Institutional Investors Weigh In On BiomX

A number of large investors have recently bought and sold shares of PHGE. JPMorgan Chase & Co. acquired a new stake in shares of BiomX in the 4th quarter worth about $314,000. Allostery Investments LP bought a new stake in BiomX during the 4th quarter worth approximately $470,000. Alyeska Investment Group L.P. purchased a new stake in shares of BiomX in the fourth quarter worth approximately $632,000. Finally, Ikarian Capital LLC bought a new position in shares of BiomX in the third quarter valued at approximately $911,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.